Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939568 | 0.94 | PPARG (0.40) | PPARGTRPV1RXFP1MAOBMAPK1 | |
| SCHEMBL9939578 | 0.93 | CNR2 (0.41) | PPARGRXFP1MAOBMAPK1ERCC1 | |
| SCHEMBL9939575 | 0.93 | TRPV1 (0.42) | PPARGTRPV1MAOBMAPK1MAPK10 | |
| SCHEMBL9939640 | 0.92 | RXFP1 (0.40) | PPARGTRPV1RXFP1ERCC1ERCC4 | |
| SCHEMBL17279293 | 0.92 | PPARG (0.43) | PPARGTRPV1MAOBMAPK1MAPK10 | |
| SCHEMBL9938508 | 0.91 | RXFP1 (0.46) | TRPV1RXFP1 | |
| SCHEMBL9938512 | 0.90 | PPARG (0.40) | PPARGTRPV1MAOBMAPK1MAPK10 | |
| SCHEMBL9939182 | 0.90 | MAOB (0.40) | PPARGMAOBMAPK1MAPK10ROCK2 | |
| SCHEMBL9939674 | 0.90 | RXFP1 (0.43) | RXFP1MAOBMAPK1ROCK2ROCK1 | |
| SCHEMBL9939656 | 0.90 | LMNA (0.41) | TRPV1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2648710-B1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2012078869-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | PPARG 1784/4885TRPV1 3332/4885RXFP1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.